非アルコール性脂肪性肝炎（NASH）薬の世界市場2020年：企業別、地域別、種類・用途別

• 英文タイトル：Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：D0GIR-01947 • 出版社/出版日：GlobalInfoResearch / 2020年9月23日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、103ページ • 納品方法：Eメール • 産業分類：医療、製薬、バイオ

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートでは、非アルコール性脂肪性肝炎（NASH）薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。非アルコール性脂肪性肝炎（NASH）薬の種類別市場規模（ビタミンE・ピオグリタゾン、オベチコール酸（OCA）、エラフィブラノール、セロンサーチブ・セニクリビロック）、用途別市場規模（病院薬局、オンラインプロバイダー、小売薬局）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：AstraZeneca、Immuron、Galmed Pharmaceuticals、Conatus Pharmaceuticals、Horizon Pharma、Enzo Biochem、Novo Nordisk、Gilead、Genfit、Intercept Pharmaceuticals ・地域別グローバル市場分析 2015年-2020年 ・非アルコール性脂肪性肝炎（NASH）薬の北米市場（アメリカ、カナダ、メキシコ） ・非アルコール性脂肪性肝炎（NASH）薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・非アルコール性脂肪性肝炎（NASH）薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・非アルコール性脂肪性肝炎（NASH）薬の南米市場（ブラジル、アルゼンチン） ・非アルコール性脂肪性肝炎（NASH）薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：ビタミンE・ピオグリタゾン、オベチコール酸（OCA）、エラフィブラノール、セロンサーチブ・セニクリビロック ・用途別分析：病院薬局、オンラインプロバイダー、小売薬局 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論

Market Overview
The global Non-Alcoholic Steatohepatitis (NASH) Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Non-Alcoholic Steatohepatitis (NASH) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Non-Alcoholic Steatohepatitis (NASH) Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Non-Alcoholic Steatohepatitis (NASH) Drugs market has been segmented into:
Vitamin E & Pioglitazone
Obeticholic Acid (OCA)
Elafibranor
Selonsertib & Cenicriviroc

By Application, Non-Alcoholic Steatohepatitis (NASH) Drugs has been segmented into:
Hospital Pharmacy
Online Provider
Retail Pharmacy

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Non-Alcoholic Steatohepatitis (NASH) Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Non-Alcoholic Steatohepatitis (NASH) Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Non-Alcoholic Steatohepatitis (NASH) Drugs market.

The report offers in-depth assessment of the growth and other aspects of the Non-Alcoholic Steatohepatitis (NASH) Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share Analysis
Non-Alcoholic Steatohepatitis (NASH) Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Non-Alcoholic Steatohepatitis (NASH) Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Non-Alcoholic Steatohepatitis (NASH) Drugs sales, revenue and market share for each player covered in this report.

The major players covered in Non-Alcoholic Steatohepatitis (NASH) Drugs are:
AstraZeneca
Immuron
Galmed Pharmaceuticals
Conatus Pharmaceuticals
Horizon Pharma
Enzo Biochem
Novo Nordisk
Gilead
Genfit
Intercept Pharmaceuticals

レポート目次

---

Table of Contents

1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Overview
1.1 Product Overview and Scope of Non-Alcoholic Steatohepatitis (NASH) Drugs
1.2 Classification of Non-Alcoholic Steatohepatitis (NASH) Drugs by Type
1.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Type in 2019
1.2.3 Vitamin E & Pioglitazone
1.2.4 Obeticholic Acid (OCA)
1.2.5 Elafibranor
1.2.6 Selonsertib & Cenicriviroc
1.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market by Application
1.3.1 Overview: Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital Pharmacy
1.3.3 Online Provider
1.3.4 Retail Pharmacy
1.4 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market by Regions
1.4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Non-Alcoholic Steatohepatitis (NASH) Drugs (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Non-Alcoholic Steatohepatitis (NASH) Drugs Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Non-Alcoholic Steatohepatitis (NASH) Drugs Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Non-Alcoholic Steatohepatitis (NASH) Drugs Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Non-Alcoholic Steatohepatitis (NASH) Drugs Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Non-Alcoholic Steatohepatitis (NASH) Drugs Status and Prospect (2015-2025)
2 Company Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 AstraZeneca SWOT Analysis
2.1.4 AstraZeneca Product and Services
2.1.5 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.2 Immuron
2.2.1 Immuron Details
2.2.2 Immuron Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Immuron SWOT Analysis
2.2.4 Immuron Product and Services
2.2.5 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.3 Galmed Pharmaceuticals
2.3.1 Galmed Pharmaceuticals Details
2.3.2 Galmed Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Galmed Pharmaceuticals SWOT Analysis
2.3.4 Galmed Pharmaceuticals Product and Services
2.3.5 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.4 Conatus Pharmaceuticals
2.4.1 Conatus Pharmaceuticals Details
2.4.2 Conatus Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Conatus Pharmaceuticals SWOT Analysis
2.4.4 Conatus Pharmaceuticals Product and Services
2.4.5 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.5 Horizon Pharma
2.5.1 Horizon Pharma Details
2.5.2 Horizon Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Horizon Pharma SWOT Analysis
2.5.4 Horizon Pharma Product and Services
2.5.5 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.6 Enzo Biochem
2.6.1 Enzo Biochem Details
2.6.2 Enzo Biochem Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Enzo Biochem SWOT Analysis
2.6.4 Enzo Biochem Product and Services
2.6.5 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.7 Novo Nordisk
2.7.1 Novo Nordisk Details
2.7.2 Novo Nordisk Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Novo Nordisk SWOT Analysis
2.7.4 Novo Nordisk Product and Services
2.7.5 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.8 Gilead
2.8.1 Gilead Details
2.8.2 Gilead Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Gilead SWOT Analysis
2.8.4 Gilead Product and Services
2.8.5 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.9 Genfit
2.9.1 Genfit Details
2.9.2 Genfit Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Genfit SWOT Analysis
2.9.4 Genfit Product and Services
2.9.5 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Gross Margin and Market Share (2018-2019)
2.10 Intercept Pharmaceuticals
2.10.1 Intercept Pharmaceuticals Details
2.10.2 Intercept Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Intercept Pharmaceuticals SWOT Analysis
2.10.4 Intercept Pharmaceuticals Product and Services
2.10.5 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Non-Alcoholic Steatohepatitis (NASH) Drugs Players Market Share
3.2.2 Top 10 Non-Alcoholic Steatohepatitis (NASH) Drugs Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Market Share by Regions
4.2 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
4.3 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
4.5 South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
5 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Countries
5.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Countries (2015-2020)
5.2 USA Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
5.3 Canada Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
5.4 Mexico Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
6 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Countries
6.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Countries (2015-2020)
6.2 Germany Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
6.3 UK Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
6.4 France Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
6.5 Russia Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
6.6 Italy Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Countries
7.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Countries (2015-2020)
7.2 China Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
7.3 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
7.4 Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
7.5 India Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
8 South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Countries
8.1 South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Countries (2015-2020)
8.2 Brazil Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
8.3 Argentina Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Non-Alcoholic Steatohepatitis (NASH) Drugs by Countries
9.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Countries (2015-2020)
9.2 Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
9.3 UAE Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
9.4 Egypt Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
9.5 South Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Market Share by Type (2015-2020)
10.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Forecast by Type (2019-2024)
10.3 Vitamin E & Pioglitazone Revenue Growth Rate (2015-2025)
10.4 Obeticholic Acid (OCA) Revenue Growth Rate (2015-2025)
10.5 Elafibranor Revenue Growth Rate (2015-2025)
10.6 Selonsertib & Cenicriviroc Revenue Growth Rate (2015-2025)
11 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Segment by Application
11.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Application (2015-2020)
11.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Forecast by Application (2019-2024)
11.3 Hospital Pharmacy Revenue Growth (2015-2020)
11.4 Online Provider Revenue Growth (2015-2020)
11.5 Retail Pharmacy Revenue Growth (2015-2020)
12 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast (2021-2025)
12.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Forecast (2021-2025)
12.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Forecast by Regions (2021-2025)
12.3 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Forecast (2021-2025)
12.4 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Forecast (2021-2025)
12.6 South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Non-Alcoholic Steatohepatitis (NASH) Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. AstraZeneca Corporate Information, Location and Competitors
Table 6. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Major Business
Table 7. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Total Revenue (USD Million) (2017-2018)
Table 8. AstraZeneca SWOT Analysis
Table 9. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
Table 10. AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Immuron Corporate Information, Location and Competitors
Table 12. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Major Business
Table 13. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Total Revenue (USD Million) (2018-2019)
Table 14. Immuron SWOT Analysis
Table 15. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
Table 16. Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Galmed Pharmaceuticals Corporate Information, Location and Competitors
Table 18. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Major Business
Table 19. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Total Revenue (USD Million) (2017-2018)
Table 20. Galmed Pharmaceuticals SWOT Analysis
Table 21. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
Table 22. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Conatus Pharmaceuticals Corporate Information, Location and Competitors
Table 24. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Major Business
Table 25. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Total Revenue (USD Million) (2017-2018)
Table 26. Conatus Pharmaceuticals SWOT Analysis
Table 27. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
Table 28. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Horizon Pharma Corporate Information, Location and Competitors
Table 30. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Major Business
Table 31. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Total Revenue (USD Million) (2017-2018)
Table 32. Horizon Pharma SWOT Analysis
Table 33. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
Table 34. Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Enzo Biochem Corporate Information, Location and Competitors
Table 36. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Major Business
Table 37. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Total Revenue (USD Million) (2017-2018)
Table 38. Enzo Biochem SWOT Analysis
Table 39. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
Table 40. Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Novo Nordisk Corporate Information, Location and Competitors
Table 42. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Major Business
Table 43. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Total Revenue (USD Million) (2017-2018)
Table 44. Novo Nordisk SWOT Analysis
Table 45. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
Table 46. Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Gilead Corporate Information, Location and Competitors
Table 48. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Major Business
Table 49. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Total Revenue (USD Million) (2017-2018)
Table 50. Gilead SWOT Analysis
Table 51. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
Table 52. Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Genfit Corporate Information, Location and Competitors
Table 54. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Major Business
Table 55. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Total Revenue (USD Million) (2017-2018)
Table 56. Genfit SWOT Analysis
Table 57. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
Table 58. Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Intercept Pharmaceuticals Corporate Information, Location and Competitors
Table 60. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Major Business
Table 61. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Total Revenue (USD Million) (2017-2018)
Table 62. Intercept Pharmaceuticals SWOT Analysis
Table 63. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Product and Solutions
Table 64. Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (Million USD) by Players (2015-2020)
Table 66. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Share by Players (2015-2020)
Table 67. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (Million USD) by Regions (2015-2020)
Table 68. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Regions (2015-2020)
Table 69. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Countries (2015-2020)
Table 70. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Countries (2015-2020)
Table 71. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (Million USD) by Countries (2015-2020)
Table 72. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (Million USD) by Countries (2015-2020)
Table 73. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Countries (2015-2020)
Table 74. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Countries (2015-2020)
Table 75. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (Million USD) by Countries (2015-2020)
Table 76. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Countries (2015-2020)
Table 77. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (Million USD) by Type (2015-2020)
Table 78. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Share by Type (2015-2020)
Table 79. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Forecast by Type (2021-2025)
Table 80. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Application (2015-2020)
Table 81. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Share by Application (2015-2020)
Table 82. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Forecast by Application (2021-2025)
Table 83. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Non-Alcoholic Steatohepatitis (NASH) Drugs Picture
Figure 2. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Type in 2019
Figure 3. Vitamin E & Pioglitazone Picture
Figure 4. Obeticholic Acid (OCA) Picture
Figure 5. Elafibranor Picture
Figure 6. Selonsertib & Cenicriviroc Picture
Figure 7. Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Application in 2019
Figure 8. Hospital Pharmacy Picture
Figure 9. Online Provider Picture
Figure 10. Retail Pharmacy Picture
Figure 11. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (USD Million) and Growth Rate (2015-2025)
Figure 12. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Share by Players in 2019
Figure 19. Global Top 5 Players Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share in 2019
Figure 20. Global Top 10 Players Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share in 2019
Figure 21. Key Players Market Share Trend
Figure 22. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 23. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Regions (2015-2020)
Figure 24. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Regions in 2018
Figure 25. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
Figure 26. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
Figure 27. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
Figure 28. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
Figure 29. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
Figure 30. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Countries (2015-2020)
Figure 31. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Countries in 2019
Figure 32. USA Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
Figure 33. Canada Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
Figure 34. Mexico Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
Figure 35. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Countries (2015-2020)
Figure 36. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Countries in 2019
Figure 37. Germany Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
Figure 38. UK Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
Figure 39. France Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
Figure 40. Russia Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
Figure 41. Italy Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
Figure 42. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Countries (2015-2020)
Figure 43. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Countries in 2019
Figure 44. China Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
Figure 45. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
Figure 46. Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
Figure 47. India Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
Figure 48. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
Figure 49. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Countries (2015-2020)
Figure 50. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Countries in 2019
Figure 51. Brazil Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
Figure 52. Argentina Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
Figure 53. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Countries (2015-2020)
Figure 54. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Countries in 2019
Figure 55. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
Figure 56. UAE Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
Figure 57. Egypt Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
Figure 58. South Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue and Growth Rate (2015-2020)
Figure 59. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Share by Type (2015-2020)
Figure 60. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Share by Type in 2019
Figure 61. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share Forecast by Type (2021-2025)
Figure 62. Global Vitamin E & Pioglitazone Revenue Growth Rate (2015-2020)
Figure 63. Global Obeticholic Acid (OCA) Revenue Growth Rate (2015-2020)
Figure 64. Global Elafibranor Revenue Growth Rate (2015-2020)
Figure 65. Global Selonsertib & Cenicriviroc Revenue Growth Rate (2015-2020)
Figure 66. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Share by Application (2015-2020)
Figure 67. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Share by Application in 2019
Figure 68. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share Forecast by Application (2021-2025)
Figure 69. Global Hospital Pharmacy Revenue Growth Rate (2015-2020)
Figure 70. Global Online Provider Revenue Growth Rate (2015-2020)
Figure 71. Global Retail Pharmacy Revenue Growth Rate (2015-2020)
Figure 72. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 73. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 74. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share Forecast by Regions (2021-2025)
Figure 75. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Forecast (2021-2025)
Figure 76. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Forecast (2021-2025)
Figure 77. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Forecast (2021-2025)
Figure 78. South America Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Forecast (2021-2025)
Figure 79. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Forecast (2021-2025)
Figure 80. Sales Channel: Direct Channel vs Indirect Channel

---